| Name: |
ALPROSTADIL (Prostaglandin E1, Prostin VRR) |
| Classification: |
arterial vasodilator; platelet-aggregation inhibitor
- used in ischemic conditions to dilate small vessels (eg. Raynaud's disease, peripheral vascular disease)
|
| Dose: |
- 5-30 ng/kg/min, titrated to patient response
|
| Administration: |
IV Infusion:
500 ug / 100 ml NS (5 ug/ml)
|
| Adverse Effects: |
- hypotension
- tachycardia
- bleeding
|
| Monitoring Therapy: |
- cutaneous vasodilation (sign of misplacement of infusion line)
- arterial pressure, HR
- peripheral perfusion
- INR/PTT
|
| CCTC Protocol: |
- May be administered by IV infusion by an approved RN in CCTC.
- Must be administered via a central line.
- Continuous infusion requires the use of an infusion pump.
|
Last Update: April 28, 2006 |
Lynne Kelly, Pharmacist, CCTC
Brenda Morgan, Clinical Nurse Specialist, CCTC
Last Update: August 7, 2006
|
Print
Handheld
Contrast
